{"entity":{"id":"idea-bio2-antimetastatic-endpoint","kind":"idea","name":"A regulatory endpoint for drugs that block spread, not tumours","aka":[],"tldr":"Today a cancer drug is approved for shrinking tumours. A drug that stopped cancer spreading would fail that test, so almost nobody develops one. A new endpoint would fix that.","summary":"Anti-metastatic agents act on dissemination, seeding and outgrowth, not on the size of existing lesions, so they look inactive by RECIST and are killed in phase 2. A qualified endpoint family (new-lesion-free survival, number of new anatomical sites over time, and site-specific metastasis-free survival) would let sponsors run trials that can succeed. Regulators already accept metastasis-free survival in non-metastatic prostate cancer, which is the precedent to generalise.","asOf":"2026-09-08","links":[{"label":"FDA Oncology Center of Excellence (page moved; nearest live section)","url":"https://www.fda.gov/about-fda/"}],"tags":[],"related":[],"cancers":["prostate","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["recist","oligometastatic","os"],"trials":[],"people":[],"bottlenecks":["b-metastasis-biology","b-trial-design"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"If FDA and EMA qualify a new-lesion-based endpoint family for the adjuvant and oligometastatic settings, at least five mechanistically anti-metastatic programmes that are currently shelved enter registrational trials within five years.","rationale":"Endpoint availability drives portfolio choices more than biology does: metastasis-free survival in the non-metastatic castration-resistant prostate trials created an entire treatment setting almost overnight. The same instrument applied to any cancer would make anti-seeding mechanisms commercially legible.","test":"A regulatory workshop plus a retrospective analysis pooling adjuvant trial datasets to show that new-lesion-free survival is estimable, reproducible across readers, and correlated with overall survival; then a formal endpoint qualification submission.","maturity":"speculative","actor":"regulator","cost":"small","horizonYears":5},"route":"/ideas/idea-bio2-antimetastatic-endpoint/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"term":[{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","route":"/terms/oligometastatic/"},{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/"},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/"}],"bottleneck":[{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"}]}}